Navigation Links
Compounds Identified That Might Treat Nerve Diseases

Researchers aim to 'chaperone' proteins involved in diseases like Parkinson's

TUESDAY, Jan. 19 (HealthDay News) -- Researchers report that they've developed a new way to find compounds that could become treatments for degenerative nerve disorders such as Alzheimer's, Huntington's and Parkinson's diseases.

The diseases cause proteins in nerve cells known as neurons to "misfold." In the new research, scientists say they've found molecules that play a role in the body's efforts to "chaperone" the molecules that fix the broken proteins.

The scientists studied one of the molecules and used rat neurons to show that it does indeed serve as a protective chaperone. Research in fruit flies showed the same thing.

Researchers say the study could lead to treatments that manipulate the chaperone molecules, leading to repair of the broken proteins.

"We found a creative way to identify new molecules that can activate the body's natural protein-folding machinery," senior author Dennis J. Thiele, professor of pharmacology and cancer biology at Duke University Medical Center in Durham, N.C., said in a news release.

The research appeared in the Jan. 19 online issue of PLoS Biology.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more on Parkinson's disease.

-- Randy Dotinga

SOURCE: Duke University, news release, Jan. 19, 2010

Copyright©2010 ScoutNews,LLC.
All rights reserved

Page: 1

Related medicine news :

1. Prenatal exposure to flame-retardant compounds affects neurodevelopment of young children
2. Marijuana Compounds Could Beat Back Brain Cancer
3. Spice Compounds May Stem Tumor Growth
4. Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
5. Study shows how to boost value of Alzheimers-fighting compounds
6. New class of compounds discovered for potential Alzheimers disease drug
7. Novel light-sensitive compounds show promise for cancer therapy
8. Neuromed Announces that Merck & Co., Inc. Terminates Research Collaboration and License Agreement for Compounds Targeting N-Type Calcium Channels
9. Research Findings on Nine GlaxoSmithKline Cancer Compounds to be Presented at ASCO 2009
10. Newly Identified Compounds May Inhibit Strep Infection
11. PRA SPEAKING EVENT: Phase I Studies with Hepatitis C Compounds in Healthy Volunteers and Patients: Views from Inside
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Wimbledon Health ... launches new Wimbledon Athletics Facebook page to educate the public, parents ... cardiac abnormalities. About 2,000 people under the age of 25 die from sudden ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... On November ... of Tri Lite’s personal heating products business. Cozy Products explains what this ... heaters that fit in well with the Cozy Products business model: to sell personal ...
(Date:11/25/2015)... ... ... SCOTTSDALE, AZ) - Today, Dr. Todd C. Hobgood ... non-surgical treatments, announced the expansion of his private practice capabilities with the grand ... trained and nationally recognized for his natural approach, Dr. Todd Hobgood serves the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Brillianteen, McGaw YMCA’s ... learning in its 65th Anniversary Brillianteen Revue, scheduled for March 4-6, 2016. Auditions ... 65 years, Brillianteen has been a treasured tradition for numerous families in the ...
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I saw a passenger ... thought there had to be a convenient and comfortable way to protect them from ... disabled individuals to safely travel during cold or inclement weather. In doing so, it ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... -- Research and Markets ( ) has ... Horizons and Growth Strategies in the Italian Therapeutic ... Forecasts, Competitive Intelligence, Emerging Opportunities" report to ... --> This new 247-page report provides ... monitoring market, including emerging tests, technologies, instrumentation, sales ...
(Date:11/25/2015)... 25, 2015  Amgen (NASDAQ: AMGN ) today ... with the United States (U.S.) ... biosimilar candidate to Humira ® (adalimumab). Amgen believes ... to the FDA and represents Amgen,s first BLA submission ... Harper , M.D., executive vice president of Research and ...
(Date:11/25/2015)... MINNEAPOLIS , Nov. 25, 2015  ARKRAY ... care products, continues to provide evidence demonstrating the accuracy ... the World Congress on Insulin Resistance, Diabetes and Cardiovascular ... showed that both the Company,s GLUCOCARD ® 01 ... met high accuracy requirements. The ability to accurately measure ...
Breaking Medicine Technology: